Smyth, Mark J <br/><br/>
IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy.  [electronic resource] 

 -  Journal of immunology (Baltimore, Md. : 1950)  May 2006 
 - 6347-55 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0022-1767 
<br/><br/><label>Standard No.: </label>10.4049/jimmunol.176.10.6347  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cell Line, Tumor<br/>Cytotoxicity, Immunologic<br/>Interleukins--administration & dosage<br/>Lymphocyte Activation--immunology<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Mice, SCID<br/>Receptors, TNF-Related Apoptosis-Inducing Ligand<br/>Receptors, Tumor Necrosis Factor--immunology<br/>T-Lymphocytes, Cytotoxic--immunology<br/>Interleukin-21